Post-ERCP Acute Pancreatitis Clinical Trial
Official title:
ERCP in Super-aged Patients Considering Difficult Cannulation: Challenges and Adverse Events
Today 11 percent of China's population is over the age of 65, and according to United Nations, it will take China just 20 years for the proportion of the elderly population to double to 25%. As life expectancy has increased, application of Endoscopic Retrograde Cholangiopancreatography (ERCP) in super-aged (≥80 years of age) is no longer limited with increasing prevalence of choledocholithiasis, and malignancy in advancing age. This increasing may come with more difficulty in cannulation or more complications in senior patients. Regarding difficult cannulation, little is known about grading difficulty in the elderly and its relation with adverse events. Therefore, it is time to evaluate the risk factors of adverse events in super-aged patients with difficult bile duct cannulation.
AIM: To evaluate the incidence, causes, and management of difficult biliary cannulation
during ERCP in elderly patients and its role as a risk factor for adverse events.
METHODS: A total of 614 patients, with a mean age of 65.3±16.7 years, underwent ERCP during
the study period, were prospectively managed and divided into two groups based on their age.
There were 146 patients aged 80 years or older in group A with the mean age of 84±3.4 years.
The primary outcome measurements were the difficulty grade of papilla cannulation, clinical
outcomes, and ERCP-related complications in the two groups. The adverse events were analyzed
by logistic regression about patient age, co-morbidities, indications, and difficult
cannulation grading.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546867 -
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
|
N/A | |
Terminated |
NCT02241512 -
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
|
Phase 2 | |
Completed |
NCT00222092 -
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
|
Phase 4 | |
Completed |
NCT05310409 -
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
|
||
Not yet recruiting |
NCT06260878 -
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT04770857 -
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
|
||
Completed |
NCT02641561 -
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
|
Phase 3 | |
Active, not recruiting |
NCT04145336 -
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
|
N/A | |
Completed |
NCT03629600 -
Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT03756116 -
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
|
N/A | |
Recruiting |
NCT05664074 -
Rectal Indomethacin vs Intravenous Ketorolac
|
Phase 4 | |
Completed |
NCT02308891 -
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05336630 -
Study of Forceps Cannulation During ERCP
|
N/A | |
Recruiting |
NCT05857514 -
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05267379 -
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
|
||
Recruiting |
NCT05947461 -
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
|
N/A | |
Completed |
NCT03098082 -
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT02830984 -
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
|
N/A | |
Recruiting |
NCT02839356 -
Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Completed |
NCT01673763 -
Post-ERCP Pancreatitis Prevention by Stent Insertion
|
N/A |